ADMA Biologics financials
$9.96−1.58%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $510.2M | $426.5M | $258.2M | $154.1M | $80.9M | $42.2M | $29.3M | $17.0M | $22.8M | $10.7M |
| Gross profit | $292.8M | $219.6M | $88.9M | $35.3M | $1.2M | -$19.1M | -$10.2M | -$25.2M | -$6.4M | $4.3M |
| Gross margin | 57.4% | 51.5% | 34.4% | 22.9% | 1.4% | −45.2% | −34.6% | −148.4% | −28.1% | 40.3% |
| Operating income | $191.4M | $139.0M | $21.6M | -$39.4M | -$58.4M | -$64.9M | -$41.4M | -$60.3M | -$39.3M | -$17.3M |
| Net income | $146.9M | $197.7M | -$28.2M | -$65.9M | -$71.6M | -$75.7M | -$48.3M | -$65.7M | -$43.8M | -$19.5M |
| Net margin | 28.8% | 46.4% | −10.9% | −42.8% | −88.5% | −179.4% | −164.5% | −387.1% | −192.3% | −183.1% |
| Diluted EPS | $0.60 | $0.81 | $-0.13 | $-0.33 | $-0.51 | $-0.88 | $-0.89 | $-1.45 | $-1.91 | $-1.61 |
| EBITDA | $199.5M | $147.0M | $30.0M | -$32.3M | -$52.9M | -$61.0M | -$38.2M | -$56.8M | -$35.8M | -$16.9M |
| Operating cash flow | $50.4M | $118.7M | $8.8M | -$59.5M | -$112.4M | -$102.0M | -$79.0M | -$62.7M | -$39.1M | -$18.3M |
| Free cash flow | $27.8M | $110.4M | $4.0M | -$73.4M | -$125.9M | -$114.7M | -$82.8M | -$64.8M | -$41.7M | -$18.3M |
| Diluted shares | 244.9M | 243.3M | 224.0M | 197.9M | 139.6M | 86.1M | 54.3M | 45.2M | 22.9M | 12.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $87.6M | $103.1M | $51.4M | $86.5M | $51.1M | $55.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $72.1M | $72.3M | $132.3M | $144.3M | $94.9M | $93.0M |
| Total assets | $624.2M | $488.7M | $329.2M | $348.5M | $276.3M | $207.7M |
| Total liabilities | $146.9M | $139.7M | $194.0M | $196.5M | $135.1M | $119.4M |
| Shareholders' equity | $477.3M | $349.0M | $135.2M | $152.0M | $141.2M | $88.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology